Table 3 Medical and family history of LFS- or HBOC-related cancers in patients undergoing tumor-only NGS assay

From: Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing

Medical and family history of LFS-related cancersa

No. of patients with variants in TP53 (%)

With possible SFs (n = 91)

Tested SangerSeq (n = 6)

With true SFs (n = 0)

In

 P + FDR + SDR

0 (0)

0 (0)

0 (–)

 P + FDR

4 (6.1)

0 (0)

0 (–)

 P + SDR

0 (0)

0 (0)

0 (–)

 P

2 (3.0)

0 (0)

0 (–)

 FDR + SDR

0 (0)

0 (0)

0 (–)

 FDR

4 (6.1)

0 (0)

0 (–)

 LFS criteria matched

0 (0)

0 (0)

0 (–)

Medical and family history of HBOC-related cancersb

No. of patients with variants in BRCA1 or BRCA2 (%)

With possible SFs (n = 11)

Tested SangerSeq (n = 3)

With true SFs (n = 3)

In

 P + FDR + SDR

0 (0)

0 (0)

0 (0)

 P + FDR

1 (9.1)

0 (0)

0 (0)

 P + SDR

0 (0)

0 (0)

0 (0)

 P

5 (45.5)

1 (33.3)

1 (33.3)

 FDR + SDR

0 (0)

0 (0)

0 (0)

 FDR

1 (9.1)

1 (33.3)

1 (33.3)

HBOC criteria matched

1 (9.1)

0 (0)

0 (0)

  1. aSarcoma, breast cancer, brain tumor, adrenocortical carcinoma, leukemia, or lung cancer
  2. bBreast cancer, ovarian cancer, prostate cancer, or pancreatic cancer
  3. SFs secondary findings, LFS Li–Fraumeni syndrome, HBOC hereditary breast and ovarian cancer, P patient, FDR first degree relatives, SDR second degree relatives
Back to article page